Drugs that demonstrated efficacy against SARS-CoV and/or MERS have been
incorporated into the WHO SOLIDARITY clinical trial. For this study,
the WHO selected the nucleotide analogue remdesivir; the antimalarial drugs
chloroquine and its analogue hydroxychloroquine; a combination of the antiretroviral
agents lopinavir and ritonavir; and this combination in conjunction with
interferon-beta.